Search

This volume includes the information necessary to understand recent critical advances in the mechanisms of intestinal tumorigenesis and to comprehend the complexity of the process. The volume aims to entice new researchers to participate in relevant studies, and to provide a forum for discussion within the scientific community to shape future research in this field. Discoveries in intestinal tumorigenesis lead to further understanding of mechanisms involved in colon cancer. Additionally, advancements in techniques and methods open the doors for new approaches to better define the molecular and organismal mechanisms of intestinal tumorigenesis. Chapters are authored by widely published authorities in the field.Each year, there are close to 150,000 new cases of colorectal cancer, which results in approximately 50,000 deaths per year in the United States; these figures render colorectal cancer a significant health concern. Studies attempting to understand the mechanisms of development and progression of colorectal cancer have been ongoing for decades and each year brings new discoveries yielding a better comprehension of the underlying processes at work.

This volume thoroughly explores of the functional role of microRNAs in cancer. It not only expertly describes the molecular mechanisms underlying the malignant transformation process but also compiles cutting-edge research on microRNAs in several forms of cancer, including colorectal cancer, pancreatic cancer, leukemia/lymphoma, prostate cancer, lung cancer, ovarian cancer, and bone cancer. Distinguished experts, currently working in prestigious institutions, elegantly discuss these fundamental themes. The text, which opens with a foreword by the renowned Dr. Carlo M. Croce, is enhanced by abundant color photographs, schemes, diagrams, and tables that fully support and complement the content.microRNA: Cancer is an ideal companion to both microRNA: Basic Science andmicroRNA: Medical Evidence. Taken together, these three books provide a state-of-the-art overview of this rapidly-expanding and fascinating field, from the molecular level to clinical practice. It will be invaluable to medical students, physicians, and researchers, as a complete and unique guide in the exploration of microRNA in basic science, cancer and clinical practice.

The field of microRNA biology is really emerging in the last couple of years. Several investigators highlighted the importance of miRNAs in cancer. Although there is so much literature on microRNAs exist, a comprehensive book is still not available. Thus this book will be a great use to the scientists in the field of cancer biology. In addition, this book will be a good source of information for undergraduate, graduate students who want to develop their research careers in cancer biology.

This volume intends to contribute to “translational medicine and biology”. By this, we mean a bi-directional process whose aim is to develop knowledge from basic science towards diagnostic and therapeutic applications and reciprocally to raise new questions for basic scientists. One general requirement for translational research is to establish a multidisciplinary knowledge base shared by the actors of various specialties. This is precisely the aim of the 12 chapters of this book. It will be useful for scientists, including PhD students, who want to become more familiar with the main concepts of NPC pathology, medical imaging and current therapeutics. Conversely, medical doctors who want to update their knowledge of NPC biology will benefit from chapters on viral and cellular oncogenesis and various aspects of host-tumor interactions.

Cancer is one of the leading killers in the world and the incidence is increasing, but most cancer patients and cancer survivors suffer much from the disease and its conventional treatments'side effects. In the past, clinical data showed that some complementary and alternative medicine (CAM) possessed anticancer abilities, but some clinicians and scientists have queried about the scientific validity of CAM due to the lack of scientific evidence. There is great demand in the knowledge gap to explore the scientific and evidence-based knowledge of CAM in the anticancer field. With this aim, a book series is needed to structurally deliver the knowledge to readers. There have been a number of publications on materia medica for various cancers in recent years, the scientific and medical community are thrust for up-to-date information that are supported by concrete laboratory evidences or clinical trials. This volume is a specialised book presenting the experimental and clinical evidences of anticancer materia medica for various cancers. This book consists of sixteen chapters, providing concise reviews and expert opinions on the recent progress of materia medica research in fourteen particular cancers from bench to bedside application. In addition, the book also includes a chapter with an overview of evidence-based materia medica for cancer chemoprevention, as well as a chapter discussing on the pharmacokinetics of anticancer materia medica. Gathering international opinion leaders'views, this volume will contribute great to the cancer, academic, and clinical community by providing evidence-based information on the anticancer effects of materia medica for various cancers. ReadershipOncologists, cancer researchers, pharmacologists, pharmaceutical specialists, Chinese medicine practitioners, medical educators, postgraduates and advanced undergraduates in biomedical disciplines, cancer caregivers, cancer patients.

Why a book dedicated to rare cancer management? Given the large variety of rare cancers,they take up a significant part of our daily practice. Therefore, we owe it to our patients with rare tumours that we use the knowledge gained in the treatment of the more common cancers to provide them with a better future. This knowledge comes from recent developments in molecular diagnostics, systemic treatments with new drugs and targeted therapies together with advanced technologies in the areas of radiology and radiation therapy. Our authors have analysed the literature and recommend treatments for rare cancers based on results from past studies. We hope that this book will be an aid to those treating rare cancer cases about which, up to now, little has been published, and will reassure our patients that they have not been forgotten.